NO20085385L - Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav - Google Patents
Tiazolforbindelser som cannabinoidreseptorligander og anvendelser deravInfo
- Publication number
- NO20085385L NO20085385L NO20085385A NO20085385A NO20085385L NO 20085385 L NO20085385 L NO 20085385L NO 20085385 A NO20085385 A NO 20085385A NO 20085385 A NO20085385 A NO 20085385A NO 20085385 L NO20085385 L NO 20085385L
- Authority
- NO
- Norway
- Prior art keywords
- compounds
- receptor ligands
- cannabinoid receptor
- thiazole compounds
- compositions
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
- C07D277/62—Benzothiazoles
- C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D277/82—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/48—Acylated amino or imino radicals by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof, e.g. carbonylguanidines
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D477/00—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring
- C07D477/10—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2
- C07D477/12—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6
- C07D477/14—Heterocyclic compounds containing 1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula:, e.g. carbapenicillins, thienamycins; Such ring systems being further condensed, e.g. 2,3-condensed with an oxygen-, nitrogen- or sulphur-containing hetero ring with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 4, and with a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, e.g. an ester or nitrile radical, directly attached in position 2 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 6 with hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US80971206P | 2006-05-31 | 2006-05-31 | |
PCT/US2007/069921 WO2007140385A2 (en) | 2006-05-31 | 2007-05-30 | Thiazole compounds as cannabinoid receptor ligands and uses thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
NO20085385L true NO20085385L (no) | 2008-12-29 |
Family
ID=38662957
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20085385A NO20085385L (no) | 2006-05-31 | 2008-12-29 | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav |
Country Status (17)
Country | Link |
---|---|
US (1) | US8546583B2 (ru) |
EP (1) | EP2038266A2 (ru) |
JP (1) | JP2009538931A (ru) |
KR (1) | KR20090018685A (ru) |
CN (2) | CN102442970A (ru) |
AU (1) | AU2007266535A1 (ru) |
BR (1) | BRPI0712720A2 (ru) |
CA (1) | CA2647597A1 (ru) |
CR (1) | CR10473A (ru) |
DO (1) | DOP2008000060A (ru) |
EC (1) | ECSP089020A (ru) |
IL (1) | IL194368A0 (ru) |
MX (1) | MX2008015217A (ru) |
NO (1) | NO20085385L (ru) |
RU (1) | RU2008152788A (ru) |
TW (1) | TW200804320A (ru) |
WO (1) | WO2007140385A2 (ru) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8841334B2 (en) * | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
CN101448800A (zh) * | 2006-05-31 | 2009-06-03 | 艾博特公司 | 作为大麻素受体配体的新型化合物及其用途 |
CN102442970A (zh) | 2006-05-31 | 2012-05-09 | 雅培制药有限公司 | 用作大麻素受体配位体的噻唑化合物及其用途 |
CA2657247A1 (en) | 2006-07-28 | 2008-01-31 | Boehringer Ingelheim International Gmbh | Compounds which modulate the cb2 receptor |
WO2008063781A2 (en) | 2006-10-12 | 2008-05-29 | Abbott Laboratories | Chemical compounds as cannabinoid receptor ligands |
US8158663B2 (en) | 2006-12-22 | 2012-04-17 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
CN101765594A (zh) | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
WO2008144360A1 (en) * | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
RU2353619C2 (ru) * | 2007-06-28 | 2009-04-27 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией антикоагулянтов, фармацевтические композиции на их основе для лечения тромботических состояний и плазмозамещающий раствор для коррекции гиперкоагуляционных нарушений при гемодилюции |
RU2354647C2 (ru) * | 2007-06-28 | 2009-05-10 | Общество С Ограниченной Ответственностью "Бионика" | Новые соединения, обладающие функцией ингибиторов тромбина, и фармацевтические композиции на их основе |
EP2025674A1 (de) | 2007-08-15 | 2009-02-18 | sanofi-aventis | Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US9193713B2 (en) * | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
EP2217565B1 (en) | 2007-11-07 | 2013-05-22 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2009067613A1 (en) * | 2007-11-21 | 2009-05-28 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands and uses thereof |
US8957063B2 (en) | 2008-02-21 | 2015-02-17 | Boehringer Ingelheim International Gmbh | Amine and ether compounds which modulate the CB2 receptor |
EP2274306A1 (en) | 2008-03-11 | 2011-01-19 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
WO2010005782A1 (en) | 2008-07-10 | 2010-01-14 | Boehringer Ingelheim International Gmbh | Sulfone compounds which modulate the cb2 receptor |
US8846730B2 (en) * | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8188135B2 (en) * | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
JP5453437B2 (ja) * | 2008-09-25 | 2014-03-26 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を選択的に調節するスルホニル化合物 |
PA8854001A1 (es) * | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
EP2384320B1 (en) | 2009-01-05 | 2015-03-04 | Boehringer Ingelheim International GmbH | Pyrrolidine compounds which modulate the cb2 receptor |
WO2010096371A2 (en) | 2009-02-18 | 2010-08-26 | Boehringer Ingelheim International Gmbh | Heterocyclic compounds which modulate the cb2 receptor |
EP2429986B1 (en) * | 2009-05-12 | 2016-11-16 | Romark Laboratories, L.C. | Haloalkyl heteroaryl benzamide compounds |
US8299103B2 (en) | 2009-06-15 | 2012-10-30 | Boehringer Ingelheim International Gmbh | Compounds which selectively modulate the CB2 receptor |
JP5756800B2 (ja) | 2009-06-16 | 2015-07-29 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Cb2受容体を調節するアゼチジン2−カルボキサミド誘導体 |
CN108042535A (zh) | 2009-06-26 | 2018-05-18 | 罗马克实验室有限公司 | 用于治疗流感的化合物和方法 |
EP2480544A1 (en) | 2009-09-22 | 2012-08-01 | Boehringer Ingelheim International GmbH | Compounds which selectively modulate the cb2 receptor |
WO2011075525A1 (en) * | 2009-12-16 | 2011-06-23 | Abbott Laboratories | Process for preparing cannabinoid receptor ligands |
EP2523936A1 (en) | 2010-01-15 | 2012-11-21 | Boehringer Ingelheim International GmbH | Compounds which modulate the cb2 receptor |
WO2011109324A1 (en) | 2010-03-05 | 2011-09-09 | Boehringer Ingelheim International Gmbh | Tetrazole compounds which selectively modulate the cb2 receptor |
WO2012012307A1 (en) | 2010-07-22 | 2012-01-26 | Boehringer Ingelheim International Gmbh | Sulfonyl compounds which modulate the cb2 rece |
WO2012120056A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US8828995B2 (en) | 2011-03-08 | 2014-09-09 | Sanofi | Branched oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof |
WO2012120052A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung |
EP2683699B1 (de) | 2011-03-08 | 2015-06-24 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
WO2012120054A1 (de) | 2011-03-08 | 2012-09-13 | Sanofi | Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung |
US9650369B2 (en) | 2012-09-28 | 2017-05-16 | Xavier University Of Louisiana | Anti-migration and anti-invasion thiazole analogs for treatment of cellular proliferative disease |
EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
US20220040180A1 (en) * | 2018-09-14 | 2022-02-10 | Spectrum Pharmaceuticals, Inc. | Kits and methods for treating cancers |
CN111548263A (zh) * | 2020-05-26 | 2020-08-18 | 江苏巨莱生物医药有限公司 | 一种用于制备邻乙氧基苯甲酰氯的工艺方法 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3533331A1 (de) | 1985-09-18 | 1987-03-26 | Heumann Ludwig & Co Gmbh | Pyridothiazolderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
TW205041B (ru) | 1989-08-07 | 1993-05-01 | Fujisawa Pharmaceutical Co | |
US6559186B1 (en) * | 1990-02-26 | 2003-05-06 | Arc 1, Inc. | Compositions and methods of treatment of sympathetically maintained pain |
EP0568096B1 (en) * | 1992-04-30 | 1998-07-29 | Hodogaya Chemical Co., Ltd. | Benzothiazole derivative and agricultural and horticultural fingicide composition containing the same |
US5654322A (en) | 1992-08-11 | 1997-08-05 | Wakunaga Seiyaku Kabushiki Kaisha | Biphenylmethane derivatives and pharmaceuticals containing the same |
MY115155A (en) | 1993-09-09 | 2003-04-30 | Upjohn Co | Substituted oxazine and thiazine oxazolidinone antimicrobials. |
PT1019385E (pt) | 1995-09-15 | 2004-06-30 | Upjohn Co | N-oxidos de aminoaril-oxazolidinona |
WO1998042703A1 (de) * | 1997-03-24 | 1998-10-01 | Basf Aktiengesellschaft | Thiazolimin-derivate |
US20030220234A1 (en) | 1998-11-02 | 2003-11-27 | Selvaraj Naicker | Deuterated cyclosporine analogs and their use as immunodulating agents |
FR2796643B1 (fr) * | 1999-07-22 | 2005-04-29 | Sod Conseils Rech Applic | Derives de 2-arylimino-2, 3-dihydrothiazoles, leurs procedes de preparation et leur utilisation therapeutique |
GB9918037D0 (en) | 1999-07-30 | 1999-09-29 | Biochemie Gmbh | Organic compounds |
AU6877300A (en) | 1999-09-14 | 2001-04-17 | Shionogi & Co., Ltd. | 2-imino-1,3-thiazine derivatives |
WO2003057693A1 (fr) * | 2001-12-28 | 2003-07-17 | Sumitomo Pharmaceuticals Co., Ltd. | Composes cycliques a 5 chainons |
DE60307268T2 (de) * | 2002-05-16 | 2007-07-26 | Bayer Cropscience Gmbh | Pestizide pyridincarbonsäureamidderivate |
WO2005058887A1 (en) | 2003-12-08 | 2005-06-30 | F. Hoffmann-La Roche Ag | Novel thiazole derivates |
ES2294494T3 (es) | 2004-04-19 | 2008-04-01 | Symed Labs Limited | Un nuevo procedimiento para la preparacion de linezolid y compuestos relacionados. |
DE602004020812D1 (de) | 2004-07-20 | 2009-06-04 | Symed Labs Ltd | Neue zwischenprodukte für linezolid und verwandte verbindungen |
EP1804823A4 (en) | 2004-09-29 | 2010-06-09 | Amr Technology Inc | NEW CYCLOSPORIN ANALOGUE AND ITS PHARMACEUTICAL APPLICATIONS |
CA2587667A1 (en) * | 2004-11-15 | 2006-05-18 | Taisho Pharmaceutical Co., Ltd. | Imine compound |
TW200700387A (en) | 2005-03-21 | 2007-01-01 | Akzo Nobel Nv | 1-benzylindole-2-carboxamide derivatives |
US7674912B2 (en) | 2005-04-25 | 2010-03-09 | H. Lundbeck A/S | Pro-drugs of N-thiazol-2-yl-benzamide derivatives |
TW200716636A (en) | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
US7514068B2 (en) | 2005-09-14 | 2009-04-07 | Concert Pharmaceuticals Inc. | Biphenyl-pyrazolecarboxamide compounds |
EP1951678A1 (en) | 2005-10-21 | 2008-08-06 | Mitsubishi Tanabe Pharma Corporation | Pyrazole compounds having cannabinoid receptor (cb1) antagonizing activity |
US8841334B2 (en) | 2006-05-31 | 2014-09-23 | Abbvie Inc. | Compounds as cannabinoid receptor ligands and uses thereof |
CN101448800A (zh) | 2006-05-31 | 2009-06-03 | 艾博特公司 | 作为大麻素受体配体的新型化合物及其用途 |
CN102442970A (zh) | 2006-05-31 | 2012-05-09 | 雅培制药有限公司 | 用作大麻素受体配位体的噻唑化合物及其用途 |
JP2009544580A (ja) | 2006-06-27 | 2009-12-17 | アボット・ラボラトリーズ | チアゾリンおよびオキサゾリン誘導体ならびにそれらの使用方法 |
US8796267B2 (en) | 2006-10-23 | 2014-08-05 | Concert Pharmaceuticals, Inc. | Oxazolidinone derivatives and methods of use |
US8158663B2 (en) | 2006-12-22 | 2012-04-17 | Abbott Laboratories | Compounds as cannabinoid receptor ligands and uses thereof |
CN101616902B (zh) | 2007-02-15 | 2013-03-27 | 弗·哈夫曼-拉罗切有限公司 | 作为taar1配体的2-氨基*唑啉类化合物 |
CN101765594A (zh) * | 2007-03-28 | 2010-06-30 | 雅培制药有限公司 | 作为大麻素受体配体的1,3-噻唑-2(3h)-亚基化合物 |
US7872033B2 (en) | 2007-04-17 | 2011-01-18 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
CA2686545C (en) | 2007-04-19 | 2010-11-02 | Concert Pharmaceuticals Inc. | Deuterated morpholinyl compounds |
WO2008144360A1 (en) | 2007-05-18 | 2008-11-27 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
US7531685B2 (en) | 2007-06-01 | 2009-05-12 | Protia, Llc | Deuterium-enriched oxybutynin |
WO2009035598A1 (en) | 2007-09-10 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Deuterated pirfenidone |
US20090118238A1 (en) | 2007-09-17 | 2009-05-07 | Protia, Llc | Deuterium-enriched alendronate |
US20090088416A1 (en) | 2007-09-26 | 2009-04-02 | Protia, Llc | Deuterium-enriched lapaquistat |
US20090082471A1 (en) | 2007-09-26 | 2009-03-26 | Protia, Llc | Deuterium-enriched fingolimod |
JP2010540635A (ja) | 2007-10-02 | 2010-12-24 | コンサート ファーマシューティカルズ インコーポレイテッド | ピリミジンジオン誘導体 |
US9193713B2 (en) | 2007-10-12 | 2015-11-24 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US20090105338A1 (en) | 2007-10-18 | 2009-04-23 | Protia, Llc | Deuterium-enriched gabexate mesylate |
WO2009051782A1 (en) | 2007-10-18 | 2009-04-23 | Concert Pharmaceuticals Inc. | Deuterated etravirine |
EP2217548A1 (en) | 2007-10-26 | 2010-08-18 | Concert Pharmaceuticals Inc. | Deuterated darunavir |
WO2009067613A1 (en) | 2007-11-21 | 2009-05-28 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands and uses thereof |
EP2274306A1 (en) | 2008-03-11 | 2011-01-19 | Abbott Laboratories | Novel compounds as cannabinoid receptor ligands |
US8846730B2 (en) | 2008-09-08 | 2014-09-30 | Abbvie Inc. | Compounds as cannabinoid receptor ligands |
US8188135B2 (en) | 2008-09-16 | 2012-05-29 | Abbott Laboratories | Compounds as cannabinoid receptor ligands |
PA8854001A1 (es) | 2008-12-16 | 2010-07-27 | Abbott Lab | Compuestos novedosos como ligandos de receptores de canabinoides |
-
2007
- 2007-05-30 CN CN201110260484XA patent/CN102442970A/zh active Pending
- 2007-05-30 JP JP2009513427A patent/JP2009538931A/ja active Pending
- 2007-05-30 KR KR1020087032196A patent/KR20090018685A/ko not_active Application Discontinuation
- 2007-05-30 CA CA002647597A patent/CA2647597A1/en not_active Abandoned
- 2007-05-30 CN CNA2007800198538A patent/CN101454302A/zh active Pending
- 2007-05-30 AU AU2007266535A patent/AU2007266535A1/en not_active Abandoned
- 2007-05-30 MX MX2008015217A patent/MX2008015217A/es not_active Application Discontinuation
- 2007-05-30 BR BRPI0712720-0A patent/BRPI0712720A2/pt not_active IP Right Cessation
- 2007-05-30 WO PCT/US2007/069921 patent/WO2007140385A2/en active Application Filing
- 2007-05-30 RU RU2008152788/04A patent/RU2008152788A/ru not_active Application Discontinuation
- 2007-05-30 EP EP07797862A patent/EP2038266A2/en not_active Ceased
- 2007-05-30 US US11/755,434 patent/US8546583B2/en active Active
- 2007-05-31 TW TW096119647A patent/TW200804320A/zh unknown
-
2008
- 2008-09-25 IL IL194368A patent/IL194368A0/en unknown
- 2008-11-27 DO DO2008000060A patent/DOP2008000060A/es unknown
- 2008-11-28 CR CR10473A patent/CR10473A/es unknown
- 2008-12-29 EC EC2008009020A patent/ECSP089020A/es unknown
- 2008-12-29 NO NO20085385A patent/NO20085385L/no not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
EP2038266A2 (en) | 2009-03-25 |
AU2007266535A1 (en) | 2007-12-06 |
US20080058335A1 (en) | 2008-03-06 |
DOP2008000060A (es) | 2009-01-15 |
IL194368A0 (en) | 2009-08-03 |
CN101454302A (zh) | 2009-06-10 |
ECSP089020A (es) | 2009-01-30 |
MX2008015217A (es) | 2008-12-12 |
WO2007140385A3 (en) | 2008-02-07 |
CR10473A (es) | 2009-01-12 |
JP2009538931A (ja) | 2009-11-12 |
BRPI0712720A2 (pt) | 2012-11-20 |
RU2008152788A (ru) | 2010-07-10 |
US8546583B2 (en) | 2013-10-01 |
CN102442970A (zh) | 2012-05-09 |
WO2007140385A2 (en) | 2007-12-06 |
CA2647597A1 (en) | 2007-12-06 |
TW200804320A (en) | 2008-01-16 |
KR20090018685A (ko) | 2009-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20085385L (no) | Tiazolforbindelser som cannabinoidreseptorligander og anvendelser derav | |
MX2010005649A (es) | Compuestos novedosos como ligandos del receptor canabinoide y sus usos. | |
WO2007140439A3 (en) | Compounds as cannabinoid receptor ligands and uses thereof | |
NO20085060L (no) | Triazolpyrazinderivater anvendelige som anti-cancermidler | |
PH12013500745A1 (en) | Azaadamantane derivatives and methods of use | |
NO20076196L (no) | Nye 2-azetidinonderivater som kolesterolabsorpsjonsinhibitorer for behandling av hyperlipidemiske tilstander | |
WO2007103550A3 (en) | Substituted aminothiazole derivatives with anti-hcv activity | |
ATE530519T1 (de) | Cyclobutylaminderivate | |
NO20076197L (no) | Nye 2-azetidinonderivater anvendbare i behandling av hyperlipidemiske tilstander | |
TW200833675A (en) | Nicotinamide derivatives | |
NO20084278L (no) | Bezothiazol derivatives as beta2 adrenoreceptor agonists | |
NO20074093L (no) | Fremgangsmater for fremstilling av glukopyranosyl-substituerte benzyl-benzenderivater og mellomprodukter derav | |
NO20075082L (no) | Pyridin-3-karboksamidderivater som CB1-inversagonister | |
NO20075626L (no) | Heteroarylbenzamid-derivater for anvendelse som GLK-aktivatorer i behandling av diabetes | |
NO20081217L (no) | Nye benzotiazolonderivater | |
MX2009011205A (es) | Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide. | |
NO20084363L (no) | 2-Substituerte 4-benzylftalazinonderivater som histamin H1- og H3-antagonister | |
NO20081315L (no) | Benzokinazolinderivater og deres anvendelse ved behandling av benlidelser | |
NO20084005L (no) | Aminderivater | |
NO20083434L (no) | Benzamid- og heteroarenderivater | |
NO20090755L (no) | Amino-imidazoloner og deres anvendelse som et medikament for behandling av kognitiv svekkelse, Alzheimers sykdom, neurodegenerering og demens | |
NO20055688L (no) | Organiske forbindelser | |
WO2008040649A3 (en) | Pyrazine-2-carboxamide derivatives as cb2 receptor modulators | |
NO20082136L (no) | 1,5-substituerte indol-2-yl-amidderivater | |
NO20083057L (no) | Sulfonyl substituerte 1H-indoler som ligander til 5-hydroksytryptamin reseptorer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FC2A | Withdrawal, rejection or dismissal of laid open patent application | ||
FC2A | Withdrawal, rejection or dismissal of laid open patent application |